Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | unspecified PARP inhibitor |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| unspecified PARP inhibitor | PARP Inhibitor (Pan) 29 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RAD51D del | ovarian cancer | predicted - sensitive | unspecified PARP inhibitor | Case Reports/Case Series | Actionable | In a clinical study, PARP inhibitor monotherapy (niraparib (n=1), olaparib (n=5) or rucaparib (n=2)), resulted in a median progression-free survival (PFS) of 25.4 mo and an overall survival (OS) of 51.8 mo in ovarian cancer patients with homozygous deletion of homologous recombination repair (HRR) genes (n=8) including RAD51D (n=1), compared to a median PFS of 4.9 mo and OS of 18.5 mo in patients without HRR gene alterations (n=198) (PMID: 42133897). | 42133897 |
| ATM inact mut | prostate cancer | no benefit | unspecified PARP inhibitor | Clinical Study - Meta-analysis | Actionable | In a combined analysis of 6 clinical trials, PARP inhibitor therapy did not benefit patients with metastatic castration-resistant prostate cancer harboring ATM mutations compared to placebo, with an HR of 1.05 (19 vs 19 mo) for radiographic progression-free survival and 1.18 (33 vs 33 mo) for overall survival when combined with AR pathway inhibitors, and an objective response rate of 7% (5/70) as monotherapy (PMID: 38484203; NCT02987543, NCT03732820, NCT03395197, NCT03748641, NCT02952534, NCT03148795). | 38484203 |
| RAD51C del | ovarian cancer | predicted - sensitive | unspecified PARP inhibitor | Case Reports/Case Series | Actionable | In a clinical study, PARP inhibitor monotherapy (niraparib (n=1), olaparib (n=5) or rucaparib (n=2)), resulted in a median progression-free survival (PFS) of 25.4 mo and an overall survival (OS) of 51.8 mo in ovarian cancer patients with homozygous deletion of homologous recombination repair (HRR) genes (n=8) including RAD51C (n=1), compared to a median PFS of 4.9 mo and OS of 18.5 mo in patients without HRR gene alterations (n=198) (PMID: 42133897). | 42133897 |
| CHEK2 inact mut | prostate cancer | no benefit | unspecified PARP inhibitor | Clinical Study - Meta-analysis | Actionable | In a combined analysis of 6 clinical trials, PARP inhibitor therapy did not benefit patients with metastatic castration-resistant prostate cancer harboring CHEK2 mutations compared to placebo, with an HR of 1.06 (14 vs 18 mo) for radiographic progression-free survival and 1.53 (26 vs 34 mo) for overall survival when combined with AR pathway inhibitors, and an objective response rate of 0% (0/17) as monotherapy (PMID: 38484203; NCT02987543, NCT03732820, NCT03395197, NCT03748641, NCT02952534, NCT03148795). | 38484203 |
| RAD51B del | ovarian cancer | predicted - sensitive | unspecified PARP inhibitor | Case Reports/Case Series | Actionable | In a clinical study, PARP inhibitor monotherapy (niraparib (n=1), olaparib (n=5) or rucaparib), resulted in a median progression-free survival (PFS) of 25.4 mo and an overall survival (OS) of 51.8 mo in ovariant patients with homozygous deletion of homologous recombination repair (HRR) genes (n=8), including RAD51B (n=1), compared to a median PFS of 4.9 mo and OS of 18.5 mo in patients without HRR gene alterations (n=198) (PMID: 42133897). | 42133897 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST